CHA Selects Cepheid as Vendor of Choice for Molecular MRSA Tests | GenomeWeb
NEW YORK (GenomeWeb News) – Cepheid said yesterday that the Connecticut Hospital Association Shared Services Program for molecular surveillance of methicillin-resistant Staphylococcus aureus has selected Cepheid as its vendor of choice for the tests.
 
The CHA, which has 164 acute-care member hospitals, will exclusively market Cepheid’s GeneXpert Systems and Xpert MRSA test to its hospitals at pre-negotiated prices.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.